Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Home on the range where the buffalo roam -- Ignore unavailable to you. Want to Upgrade?

To: DaYooper who wrote (11289)	9/19/2003 11:16:12 AM
From: Venkie	Respond to of 13815

18 (PDLI) 14.73 +0.61: -- Update -- Fortis upgrades to Buy from Hold following the co's announcement that it has extended its antibody patent licensing agreement with DNA for an additional 5 year period; in addition, firm believes PDLI's pipeline offers the most intriguing line of therapeutic antibodies for the treatment of gastrointestinal inflammatory disease, and with $800 mln in cash and a proven proprietary antibody humanization platform with which to work, the co has the resources to develop many more products and to aggressively litigate any patent infringement cases it deems worthy.